Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 4, 2015, Pages 507-514

  O'Dwyer, David N ^a,b   Armstrong, Michelle E ^a,b   Kooblall, Minesh ^a,b   Donnelly, Seamas C ^c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Idiopathic pulmonary fibrosis; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR 3; TLR3 PROTEIN, HUMAN;

ANTIGEN RECOGNITION; FIBROSING ALVEOLITIS; GENOMICS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LUNG INJURY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; VIRUS INFECTION; ANIMAL; CLINICAL TRIAL (TOPIC); GENETICS; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNITY, INNATE; MOLECULAR TARGETED THERAPY; PHENOTYPE; TOLL-LIKE RECEPTOR 3;

EID: 84924865270     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.988706     Document Type: Review

References (70)

1. Richeldi L, Davies HR, Ferrara G, et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003(3):CD002880
2. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010(9):CD003134
3. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824
4. Uhal BD, Joshi I, Hughes WF, et al. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998;275(6 Pt 1):L1192-9
5. Li Y, Jiang D, Liang J, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011;208(7):1459-71
6. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011;66(6):462-7
7. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364(16):1503-12
8. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013;1(4):309-17
9. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142(12 Pt 1):963-7
10. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164(7):1171-81
11. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013;45(6):613-20
12. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;185(1):67-76
13. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009;135(6):1557-63
14. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179(8):717-23
15. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5(4):e93
16. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013;5(205):205ra136
17. O'Dwyer DN, Armstrong ME, Trujillo G, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013;188(12):1442-50
18. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11(5):373-84
19. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413(6857):732-8
20. Bernard JJ, Cowing-Zitron C, Nakatsuji T, et al. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat Med 2012;18(8):1286-90
21. Hasan UA, Caux C, Perrot I, et al. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci USA 2007;104(19):8047-52
22. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118(2):229-41
23. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86(6):973-83
24. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388(6640):394-7
25. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
26. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34(5):637-50
27. Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005;174(5):2942-50
28. Roach JC, Glusman G, Rowen L, et al. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 2005;102(27):9577-82
29. Bowie A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000;67(4):508-14
30. Botos I, Segal DM, Davies DR. The structural biology of Toll-like receptors. Structure 2011;19(4):447-59
31. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7(5):353-64
32. Hasan UA, Trinchieri G, Vlach J. Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J Biol Chem 2005;280(21):20620-7
33. Donnelly SC. Review series - inflammation & fibrosis. Introduction. QJM 2012;105(6):503
34. Mahendran S, Sethi T. Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach? QJM 2012;105(10):929-34
35. Olson AL, Swigris JJ, Brown KK. Clinical trials and tribulations - lessons from pulmonary fibrosis. QJM 2012;105(11):1043-7
36. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071-82
37. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083-92
38. Adamali HI, Maher TM. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther 2012;6:261-72
39. Fang F, Ooka K, Sun X, et al. A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling. J Immunol 2013;191(6):2956-66
40. Ichikawa T, Sugiura H, Koarai A, et al. TLR3 activation augments matrix metalloproteinase production through reactive nitrogen species generation in human lung fibroblasts. J Immunol 2014;192(11):4977-88
41. Cavassani KA, Ishii M, Wen H, et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med 2008;205(11):2609-21
42. Lai Y, Di Nardo A, Nakatsuji T, et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 2009;15(12):1377-82
43. Murray LA, Knight DA, McAlonan L, et al. Deleterious role of TLR3 during hyperoxia induced acute lung injury. Am J Respir Crit Care Med 2008;178:1227-37
44. Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274(16):10689-92
45. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998;395(6699):284-8
46. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282(5396):2085-8
47. Shimada T, Matsumoto M, Tatsumi Y, et al. A novel lipopolysaccharide inducible C-C chemokine receptor related gene in murine macrophages. FEBS Lett 1998;425(3):490-4
48. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005;11(11):1173-9
49. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279(9):7370-7
50. Hamada N, Maeyama T, Kawaguchi T, et al. The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008;39(4):440-7
51. Yang HZ, Cui B, Liu HZ, et al. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol 2009;182(1):692-702
52. Maher TM, Evans IC, Bottoms SE, et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;182(1):73-82
53. Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178(8):838-46
54. Plataki M, Koutsopoulos AV, Darivianaki K, et al. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 2005;127(1):266-74
55. Ramachandran P, Iredale JP. Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM 2012;105(9):813-17
56. Eickelberg O, Pansky A, Koehler E, et al. Molecular mechanisms of TGF-(beta) antagonism by interferon-gamma and cyclosporine A in lung fibroblasts. FASEB J 2001;15:797-806
57. Duncan MR, Berman B. Persistence of a reduced collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 1987;79:1318-24
58. Giri SN, Hyde DM, Marafino BJ Jr. Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice. Biochem Med Metab Biol 1986;36:194-7
59. Azuma A, Li YJ, Abe S, et al. Interferon-beta inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-beta and thrombospondin. Am J Respir Cell Mol Biol 2005;32:93-8
60. Vannella KM, Luckhardt TR, Wilke CA, et al. Latent herpes virus infection augments experimental pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:465-77
61. McMillan TR, Moore BB, Weinberg JB, et al. Exacerbations of established pulmonary fibrosis in a murine model of gammaherpesvirus. Am J Respir Crit Care Med 2008;177:771-80
62. Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999;159(4 Pt 1):1336-41
63. Egan JJ, Stewart JP, Hasleton PS, et al. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995;50(12):1234-9
64. Malizia AP, Keating DT, Smith SM, et al. Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGFbeta1 expression. Am J Physiol Lung Cell Mol Physiol 2008;295(3):L451-60
65. Tsukamoto K, Hayakawa H, Sato A, et al. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 2000;55(11):958-61
66. Pulkkinen V, Salmenkivi K, Kinnula VL, et al. A novel screening method detects herpesviral DNA in the idiopathic pulmonary fibrosis lung. Ann Med 2012;44(2):178-86
67. Tang YW, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003;41(6):2633-40
68. Ranjith-Kumar CT, Miller W, Sun J, et al. Effects of single nucleotide polymorphisms on Toll-like receptor 3 activity and expression in cultured cells. J Biol Chem 2007;282(24):17696-705
69. Noth I, Kaminski N. Idiopathic pulmonary fibrosis: time to get personal?Am J Respir Crit Care Med 2014;188:1392-4
70. Raghu G, Bozic C, Brown K, et al. Feasibility of a trial of interferon beta-1A (IFN- Beta-1A) in the treatment of Idiopathic Pulmonary Fibrosis (IPF) [abstract]. Am J Respir Crit Care Med 2001;163:A707